Geode Capital Management LLC Invests $343,000 in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Geode Capital Management LLC acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,984 shares of the company’s stock, valued at approximately $343,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. purchased a new position in Oruka Therapeutics during the third quarter valued at $11,699,000. Wellington Management Group LLP purchased a new position in Oruka Therapeutics during the third quarter valued at $2,013,000. RTW Investments LP purchased a new position in Oruka Therapeutics during the third quarter valued at $45,359,000. Redmile Group LLC purchased a new position in Oruka Therapeutics during the third quarter valued at $10,091,000. Finally, Point72 Asset Management L.P. purchased a new position in Oruka Therapeutics during the third quarter valued at $11,822,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $15.72 on Monday. The stock has a market cap of $550.18 million, a P/E ratio of -2.51 and a beta of 0.81. Oruka Therapeutics, Inc. has a twelve month low of $15.63 and a twelve month high of $53.88. The stock’s 50 day moving average is $21.72.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ORKA shares. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, December 20th. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. TD Cowen began coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating on the stock. Finally, Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.